<?xml version="1.0" encoding="UTF-8"?>
<ref id="R59">
 <label>59.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ghia</surname>
    <given-names>P</given-names>
   </name>
  </person-group>
  <article-title>Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) chronic lymphocytic leukemia: phase 3 ASCEND Study</article-title>. 
  <source>
   <italic toggle="yes">Hematol Oncol.</italic>
  </source>
  <year>2019</year>;
  <volume>37</volume>:
  <fpage>86</fpage>â€“
  <lpage>87</lpage>.
 </mixed-citation>
</ref>
